Hu Zhou | Hematology | Excellence in Research Award

Published on by Global Academic Awards

Prof. Dr. Hu Zhou | Hematology | Excellence in Research Award

Henan Cancer Hospital | China

Prof. Dr. Hu Zhou is a leading hematology researcher recognized for his extensive work on the pathogenesis and clinical management of blood disorders, particularly immune thrombocytopenia, myelodysplastic syndromes, myeloproliferative neoplasms, and thrombosis–hemostasis abnormalities. With 621 citations, 78 published documents, and an h-index of 14, he has established a strong scholarly footprint in clinical and translational hematology. His research integrates clinical trials, molecular pathology, and mechanistic studies, contributing significantly to advances in immunoglobulin therapies, monoclonal antibodies, JAK2 inhibitors, and recombinant thrombopoietic agents. He has illuminated genetic polymorphisms, cytokine signaling pathways, and immune dysregulation mechanisms underlying chronic immune thrombocytopenia. His contributions further extend to leukemogenesis, epigenetic alterations in hematologic malignancies, and therapeutic optimization in refractory leukemia. As an active member of national and international hematology societies, he leads major funded research projects and has been recognized with multiple scientific achievement awards, reflecting his broad impact on hematologic innovation and patient-centered clinical advancement.

Profile: Scopus

Featured Publications

1. Zhou, H., et al. (2025). Efficacy and safety of a new 10% intravenous immunoglobulin (IVIG) in Chinese patients with primary immune thrombocytopenia (ITP): A multicenter, single-arm, phase III trial. Clinical and Experimental Medicine.

2. Zhou, H., et al. (2025). Anti-CD38 monoclonal antibody CM313 for primary immune thrombocytopenia: Multicentre, randomised, placebo-controlled, phase 2 trial. BMJ Clinical Research Edition.

3. Zhou, H., et al. (2025). Efficacy and safety of OB756 (a novel selective JAK2 inhibitor) for essential thrombocythemia in patients intolerant of or resistant to hydroxyurea or intolerant of interferon: A phase 2, open-label, multicenter study. Cancer.

4. Zhou, H., et al. (2025). Hetrombopag for patients with persistent primary immune thrombocytopenia: A post hoc analysis of a multicenter, randomized phase III trial. Research and Practice in Thrombosis and Haemostasis.

5. Zhou, H., et al. (2025). Dose-optimised recombinant human thrombopoietin versus eltrombopag in patients with immune thrombocytopenia: A multicenter, randomised controlled trial (The TE-ITP Study). EClinicalMedicine.

Betty Pace | Hematology | Best Researcher Award

Published on by Global Academic Awards

Dr. Betty Pace | Hematology | Best Researcher Award

Dr. Betty Pace, Augusta University, United States

Dr. Betty Sue Pace, MD, is a Professor with tenure at Augusta University, serving in the Departments of Pediatrics and Biochemistry & Molecular Biology. 🧬 She holds the prestigious Francis J. Tedesco Distinguished Chair in Pediatric Hematology/Oncology and is a member of the Georgia Cancer Center. 🌟 With a medical degree from the Medical College of Wisconsin and postdoctoral training at the University of Washington, Dr. Pace is a leader in sickle cell disease research. ❤️ She has directed major research centers and served on national committees, including NIH and ASH. 📚 Her work promotes diversity, inclusion, and scientific advancement.

Publication Profile

Scopus

🎓 Education & Training

Dr. Betty Sue Pace began her academic journey at Lake Forest College in 1973, later earning her B.S. in Mathematics from Marquette University in 1976. ➗ She pursued her M.D. in Medicine at the Medical College of Wisconsin, graduating in 1981. 🩺 Dr. Pace completed her Pediatric Internship and Residency (1981–1984) at the same institution’s Children’s Hospital. 👶 She further specialized through a Pediatric Hematology/Oncology Fellowship at the University of Colorado Health Sciences Center (1987–1990). 🧬 In 1990, she briefly served as a Locum Tenens Pediatrician before undertaking a Postdoctoral Research Fellowship at the University of Washington (1990–1994).

🏅 Awards & Honors

Dr. Betty Sue Pace has received numerous prestigious accolades throughout her career. 🌟 In 1981, she was honored with the Kaiser Foundation Merit Award, Mosby Mirror Award, and Alpha Omega Alpha induction. 🏆 A Harold Amos Scholar in 1990, she was later named among Popular Science’s “Brilliant 10” in 2003. 🧪 Her work earned her Lifetime Achievement (2007), Diversity Champion (2010), and Distinguished Researcher (2022) awards. 💼 She also established endowed scholarships in her name and currently serves as Editor-in-Chief of the Journal of Sickle Cell Disease (2025). 📰 Her honors reflect a legacy of excellence in science, service, and inclusion.

Research Focus

Dr. Betty S. Pace’s research is primarily centered on sickle cell disease (SCD), with a strong focus on oxidative stress, fetal hemoglobin induction, and gene regulation. 🧬 Her work explores epigenetic therapies, histone deacetylase inhibitors, and NRF2 activation to mitigate disease symptoms. 🧫 She utilizes transgenic models, CRISPR techniques, and microRNA therapies to induce fetal hemoglobin expression and reduce ferroptosis. 💉 Her interdisciplinary research bridges molecular biology, hematology, and genomic innovation, aiming to develop novel therapeutic strategies for SCD. 🧠 Through collaborative studies and translational science, she is advancing curative solutions and improving patient outcomes worldwide.

Publication Top Notes

📄 “Transsulfuration pathway activation attenuates oxidative stress and ferroptosis…” – Communications Biology, 2025 | Cited by: 1 📚🧬

📄 “CT-101 flips the switch to fetal hemoglobin expression…” – PLOS One, 2025 🧪🧬

📄 “Innovations in Drug Discovery for SCD Targeting Oxidative Stress and NRF2…” – Review, 2025  💊🧠

📄 “Endothelial ENaC-a Restrains Oxidative Stress in Lung Capillaries…” – Am J Respir Cell Mol Biol, 2025 | Cited by: 2 🫁🔬

📄 “Hematopoietic cell transplant vs standard care in adolescents…” – Blood Advances, 2025  🧫🧒

📄 “miR-29b induces fetal haemoglobin via promoter demethylation…” – Br J Haematol, 2025 🧬🧠

📄 “Correction to: CRISPR-mediated fetal chromatin domain ablations” – Scientific Reports, 2022  🧪📘

📄 “Telehealth Use Among People with SCD During COVID-19…” – Telemedicine & e-Health, 2024 | Cited by: 1 💻📞

📄 “Simvastatin-Mediated Nrf2 Activation in SCD Mice…” – Antioxidants, 2024 | Cited by: 2 🧬🛡️

📄 “Emergency Department Visits by Individuals With SCD (1999–2020)…” – Ajpm Focus, 2024 | Cited by: 6 🏥📈

 

Angelika Bátorová | Hematology | Best Researcher Award

Published on by Global Academic Awards

Prof. Dr. Angelika Bátorová | Hematology | Best Researcher Award

Prof. Dr. Angelika Bátorová , Faculty of Medicine, Comenius Universty, Bratislava, Slovakia

Prof. Dr. Angelika Bátorová is a leading Slovak hematologist, serving as Head of the Department of Hematology and Blood Transfusion and Director of the National Hemophilia Centre at University Hospital Bratislava. A professor at Comenius University, she is recognized internationally for her work in bleeding disorders, particularly hemophilia. With clinical leadership, research innovation, and educational roles, she has significantly contributed to advancing care standards in Slovakia and Europe. She has served on the Executive Committee of the World Federation of Hemophilia and other key advisory bodies. Her dedication continues through education, patient advocacy, and clinical research in hemostasis and thrombosis.

Publication Profile

Orcid

🔹 Education

Dr. Bátorová earned her MD and PhD from the Faculty of Medicine, Comenius University in Bratislava. She trained in Internal Medicine and later specialized in Hematology and Transfusion Medicine through the University Hospital and the Institute of Postgraduate Medicine. Her postgraduate training included prestigious fellowships at the National Hemophilia Centre in Tel Aviv, Israel, and the New York Blood Center, USA. She also trained at comprehensive hemophilia care centers across Europe. Her education and training laid a strong foundation for her career in clinical hematology, research, and leadership in bleeding disorder management at both national and international levels.

🔹 Experience

Prof. Bátorová is the Head of the Department of Hematology and Transfusion Medicine and Director of the National Hemophilia Centre at University Hospital Bratislava. She is a professor of Internal Medicine at Comenius University and serves as the Chief Expert for Hematology for the Slovak Ministry of Health. Her leadership transformed Slovakia’s hemophilia care, including establishing national registries and developing clinical protocols. She has led numerous working groups, participated in international research consortia, and contributed to global medical guidelines. Her experience spans clinical management, policy development, academic leadership, and mentorship in hematology and rare bleeding disorders.

🔹 Awards and Honors

In 1996, Dr. Bátorová received the prestigious award from the World Federation of Hemophilia (WFH) for her significant contributions to improving hemophilia care in Slovakia. She served as a past Executive Committee member of the WFH and as a member of the Medical Advisory Group of the European Hemophilia Consortium. She is also a former President of the Slovak Society of Hematology. Her ongoing leadership roles include Chair of the Slovak Hemophilia Working Group and active membership in EAHAD. She continues to be recognized for her scholarly work, leadership, and global impact on hematology and patient-centered care.

🔹 Research Focus

Prof. Bátorová’s research focuses on hemostasis, thrombosis, hemophilia, and rare bleeding disorders. She was instrumental in initiating Slovakia’s National Registry of hemophilia and the Hemophilia Gene Registry. Her clinical research emphasizes pharmacokinetic-guided prophylaxis, surgery management, care for patients with inhibitors, von Willebrand disease, and congenital factor deficiencies. She has authored numerous peer-reviewed papers, textbook chapters, and conference presentations. Her work has contributed to international guidelines and improved patient outcomes. As an editorial board member and journal reviewer, she maintains an active role in advancing scientific literature and ensuring quality standards in hematology research.

Publication Top Notes

  • 📘 Physical Activity Awareness and Understanding of Treatment Protection Among People With Haemophilia and Their Caregivers in Central Europe | 📅 2025 | 📰 Haemophilia | 🔗 DOI: 10.1111/hae.70038

  • 📘 Use of thrombopoietin receptor agonists in adults with immune thrombocytopenia | 📅 2023 | 📰 Annals of Hematology | 🔗 DOI: 10.1007/s00277-023-05114-8

  • 📘 Immune tolerance induction in the era of emicizumab | 📅 2022 | 📰 Haemophilia | 🔗 DOI: 10.1111/hae.14470

  • 📘 25 years in comprehensive care and treatment of haemophilia | 📅 2019 | 📰 Transfuze a Hematologie Dnes

  • 📘 Comparison of two different techniques of warfarin dosing determination – A chemometrics study | 📅 2019 | 📰 Iranian Journal of Pharmaceutical Research | 🔗 DOI: 10.22037/ijpr.2019.1100653

  • 📘 Haematopoietic stem cell transplantation in patients with myelodysplastic syndrome – a single centre experience | 📅 2019 | 📰 Transfuze a Hematologie Dnes

  • 📘 The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab | 📅 2019 | 📰 Haemophilia | 🔗 DOI: 10.1111/hae.13762

  • 📘 The use of granulocyte colony stimulating factor after autologous hematopoietic stem cell transplantation | 📅 2019 | 📰 Bratislava Medical Journal | 🔗 DOI: 10.4149/BLL_2019_111

  • 📘 Gynaecological issues in women with bleeding disorders | 📅 2019 | 📰 The Journal of Haemophilia Practice | 🔗 DOI: 10.17225/jhp00142

  • 📘 Continuous infusion of coagulation factor concentrates during intensive treatment | 📅 2018 | 📰 Haemophilia | 🔗 DOI: 10.1111/hae.13331